Hailshadow
Vertex Pharmaceuticals (NASDAQ:VRTX) said its gene therapy Casgevy has been approved by Saudi Arabian regulators for the treatment of sickle cell disease and transfusion-dependent beta thalassemia, or TDT, in people aged 12 years or older.
The company noted that Saudi Arabia has one of the highest rates of the genetic blood disorders in the world. Vertex added that it was working to secure listings on hospital formularies to support reimbursement, according to a statement.
The FDA approved Casgevy for the treatment of sickle cell disease in December. The product was co-developed with CRISPR Therapeutics (NASDAQ:CRSP).
